Skip to main content
Erschienen in:

31.07.2024 | Head and Neck Oncology

Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System

verfasst von: Yvonne L. Eaglehouse, PhD, MPH, Sarah Darmon, PhD, Craig D. Shriver, MD, Kangmin Zhu, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to compare Asian or Pacific Islander, Black, Hispanic, and non-Hispanic White patients in treatment for papillary thyroid cancer (PTC) in the equal access Military Health System to better understand racial–ethnic cancer health disparities observed in the United States.

Methods

We used the MilCanEpi database to identify a cohort of men and women aged 18 or older who were diagnosed with PTC between 1998 and 2014. Low- or high-risk status was assigned using tumor size and lymph node involvement. Treatment with surgery (e.g., thyroidectomy) overall and treatment by risk status [active surveillance (low-risk) or adjuvant radioactive iodine (RAI) (high-risk)] was compared between racial–ethnic groups using multivariable logistic regression and expressed as adjusted odds ratios (AOR) with 95% confidence intervals (CIs).

Results

The study included 598 Asian, 553 Black, 340 Hispanic, and 2958 non-Hispanic White patients with PTC. Asian (AOR = 1.21, 95% CI 0.98, 1.49), Black (AOR = 1.07, 95% CI 0.87, 1.32), and Hispanic (AOR = 0.92, 95% CI 0.71, 1.19) patients were as likely as White patients to receive surgery. By risk status, there were no significant racial–ethnic differences in receipt of active surveillance or thyroidectomy for low-risk PTC or in thyroidectomy or total thyroidectomy with adjuvant RAI for high-risk PTC.

Conclusions

In the Military Health System, where patients have equal access to care, there were no overall racial–ethnic differences in surgical treatment for PTC. As American Thyroid Association guidelines evolve to include more conservative treatment, further research is warranted to understand potential disparities in active surveillance and surgical management in U.S. healthcare settings.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000–2013. Cureus. 2019;11(2):e4127.PubMedPubMedCentral Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of thyroid cancer: a review of the National Cancer Database, 2000–2013. Cureus. 2019;11(2):e4127.PubMedPubMedCentral
2.
Zurück zum Zitat Weeks KS, Kahl AR, Lynch CF, Charlton ME. Racial/ethnic differences in thyroid cancer incidence in the United States, 2007–2014. Cancer. 2018;124(7):1483–91.CrossRefPubMed Weeks KS, Kahl AR, Lynch CF, Charlton ME. Racial/ethnic differences in thyroid cancer incidence in the United States, 2007–2014. Cancer. 2018;124(7):1483–91.CrossRefPubMed
3.
Zurück zum Zitat Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kitahara CM, Sosa JA, Shiels MS. Influence of nomenclature changes on trends in papillary thyroid cancer incidence in the United States, 2000 to 2017. J Clin Endocrinol Metab. 2020;105(12):e4823–30.CrossRefPubMedPubMedCentral Kitahara CM, Sosa JA, Shiels MS. Influence of nomenclature changes on trends in papillary thyroid cancer incidence in the United States, 2000 to 2017. J Clin Endocrinol Metab. 2020;105(12):e4823–30.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13(4 Suppl 4):3–6.PubMedPubMedCentral Shah JP. Thyroid carcinoma: epidemiology, histology, and diagnosis. Clin Adv Hematol Oncol. 2015;13(4 Suppl 4):3–6.PubMedPubMedCentral
6.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42.CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42.CrossRefPubMed
7.
Zurück zum Zitat Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefPubMed Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefPubMed
8.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Gordon AJ, Dublin JC, Patel E, et al. American Thyroid Association guidelines and national trends in management of papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2022;148(12):1156–63.CrossRefPubMedPubMedCentral Gordon AJ, Dublin JC, Patel E, et al. American Thyroid Association guidelines and national trends in management of papillary thyroid carcinoma. JAMA Otolaryngol Head Neck Surg. 2022;148(12):1156–63.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(8):925–51.CrossRef Haddad RI, Bischoff L, Ball D, et al. Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(8):925–51.CrossRef
11.
12.
13.
Zurück zum Zitat Harari A, Li N, Yeh MW. Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2014;99(1):133–41.CrossRefPubMed Harari A, Li N, Yeh MW. Racial and socioeconomic disparities in presentation and outcomes of well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2014;99(1):133–41.CrossRefPubMed
14.
Zurück zum Zitat Davis S, Ullmann TM, Roman S. Disparities in treatment for differentiated thyroid cancer. Thyroid. 2023;33(3):287–93.CrossRefPubMed Davis S, Ullmann TM, Roman S. Disparities in treatment for differentiated thyroid cancer. Thyroid. 2023;33(3):287–93.CrossRefPubMed
15.
Zurück zum Zitat Shah SA, Adam MA, Thomas SM, et al. Racial disparities in differentiated thyroid cancer: Have we bridged the gap? Thyroid. 2017;27(6):762–72.CrossRefPubMed Shah SA, Adam MA, Thomas SM, et al. Racial disparities in differentiated thyroid cancer: Have we bridged the gap? Thyroid. 2017;27(6):762–72.CrossRefPubMed
16.
Zurück zum Zitat Jaap K, Campbell R, Dove J, et al. Disparities in the care of differentiated thyroid cancer in the United States: exploring the National Cancer Database. Am Surg. 2017;83(7):739–46.CrossRefPubMed Jaap K, Campbell R, Dove J, et al. Disparities in the care of differentiated thyroid cancer in the United States: exploring the National Cancer Database. Am Surg. 2017;83(7):739–46.CrossRefPubMed
17.
18.
Zurück zum Zitat Thiesmeyer JW, Limberg J, Ullmann TM, et al. Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma. Surgery. 2022;171(1):140–6.CrossRefPubMed Thiesmeyer JW, Limberg J, Ullmann TM, et al. Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma. Surgery. 2022;171(1):140–6.CrossRefPubMed
19.
Zurück zum Zitat Ullmann TM, Gray KD, Limberg J, et al. Insurance status is associated with extent of treatment for patients with papillary thyroid carcinoma. Thyroid. 2019;29(12):1784–91.CrossRefPubMed Ullmann TM, Gray KD, Limberg J, et al. Insurance status is associated with extent of treatment for patients with papillary thyroid carcinoma. Thyroid. 2019;29(12):1784–91.CrossRefPubMed
20.
Zurück zum Zitat Moten AS, Zhao H, Intenzo CM, Willis AI. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients. Eur J Surg Oncol. 2019;45(11):2090–5.CrossRefPubMed Moten AS, Zhao H, Intenzo CM, Willis AI. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients. Eur J Surg Oncol. 2019;45(11):2090–5.CrossRefPubMed
21.
Zurück zum Zitat Tanielian T, Farmer C. The US military health system: Promoting readiness and providing health care. Health Aff. 2019;38(8):1259–67.CrossRef Tanielian T, Farmer C. The US military health system: Promoting readiness and providing health care. Health Aff. 2019;38(8):1259–67.CrossRef
22.
Zurück zum Zitat Adirim T. A military health system for the twenty-first century. Health Aff. 2019;38(8):1268–73.CrossRef Adirim T. A military health system for the twenty-first century. Health Aff. 2019;38(8):1268–73.CrossRef
24.
Zurück zum Zitat Eaglehouse YL, Shriver CD, Lin J, et al. MilCanEpi: increased capability for cancer care research in the Department of Defense. JCO Clin Cancer Inform. 2023;7:e2300035.CrossRefPubMedPubMedCentral Eaglehouse YL, Shriver CD, Lin J, et al. MilCanEpi: increased capability for cancer care research in the Department of Defense. JCO Clin Cancer Inform. 2023;7:e2300035.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Eaglehouse YL, Park AB, Georg MW, et al. Consolidation of cancer registry and administrative claims data on cancer diagnosis and treatment in the US Military Health System. JCO Clin Cancer Inform. 2020;4:906–17.CrossRefPubMed Eaglehouse YL, Park AB, Georg MW, et al. Consolidation of cancer registry and administrative claims data on cancer diagnosis and treatment in the US Military Health System. JCO Clin Cancer Inform. 2020;4:906–17.CrossRefPubMed
26.
Zurück zum Zitat American Joint Committee on Cancer. AJCC cancer staging manual. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al., editors. 6th ed. Chicago: Springer; 2002. American Joint Committee on Cancer. AJCC cancer staging manual. In: Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al., editors. 6th ed. Chicago: Springer; 2002.
27.
Zurück zum Zitat American Joint Committee on Cancer. AJCC cancer staging manual. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Triotti A III, editors. 7th ed. Chicago: Springer; 2010. p. 648. American Joint Committee on Cancer. AJCC cancer staging manual. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Triotti A III, editors. 7th ed. Chicago: Springer; 2010. p. 648.
28.
Zurück zum Zitat Nam SH, Bae MR, Roh JL, et al. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. Oral Oncol. 2018;87:158–64.CrossRefPubMed Nam SH, Bae MR, Roh JL, et al. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma. Oral Oncol. 2018;87:158–64.CrossRefPubMed
29.
Zurück zum Zitat Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27.CrossRefPubMed
30.
Zurück zum Zitat Mehta HB, Sura SD, Adhikari D, et al. Adapting the elixhauser comorbidity index for cancer patients. Cancer. 2018;124(9):2018–25.CrossRefPubMed Mehta HB, Sura SD, Adhikari D, et al. Adapting the elixhauser comorbidity index for cancer patients. Cancer. 2018;124(9):2018–25.CrossRefPubMed
31.
Zurück zum Zitat Iñiguez-Ariza NM, Brito JP. Management of low-risk papillary thyroid cancer. Endocrinol Metab. 2018;33(2):185–94.CrossRef Iñiguez-Ariza NM, Brito JP. Management of low-risk papillary thyroid cancer. Endocrinol Metab. 2018;33(2):185–94.CrossRef
33.
Zurück zum Zitat Lohia S, Hanson M, Tuttle RM, Morris LGT. Active surveillance for patients with very low-risk thyroid cancer. Laryngoscope Investig Otolaryngol. 2020;5(1):175–82.CrossRefPubMedPubMedCentral Lohia S, Hanson M, Tuttle RM, Morris LGT. Active surveillance for patients with very low-risk thyroid cancer. Laryngoscope Investig Otolaryngol. 2020;5(1):175–82.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Griffin A, Brito JP, Bahl M, Hoang JK. Applying criteria of active surveillance to low-risk papillary thyroid cancer over a decade: How many surgeries and complications can be avoided? Thyroid. 2017;27(4):518–23.CrossRefPubMed Griffin A, Brito JP, Bahl M, Hoang JK. Applying criteria of active surveillance to low-risk papillary thyroid cancer over a decade: How many surgeries and complications can be avoided? Thyroid. 2017;27(4):518–23.CrossRefPubMed
35.
Zurück zum Zitat Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 2016;26(1):144–9.CrossRefPubMedPubMedCentral Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 2016;26(1):144–9.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Brown SR, Lee S, Brown TA, Waddell BE. Effect of race on thyroid cancer care in an equal access healthcare system. Am J Surg. 2010;199(5):685–9.CrossRefPubMed Brown SR, Lee S, Brown TA, Waddell BE. Effect of race on thyroid cancer care in an equal access healthcare system. Am J Surg. 2010;199(5):685–9.CrossRefPubMed
38.
Zurück zum Zitat Pitt SC, Yang N, Saucke MC, et al. Adoption of active surveillance for very low-risk differentiated thyroid cancer in the United States: a national survey. J Clin Endocrinol Metab. 2020;106(4):1728–37.CrossRefPubMedCentral Pitt SC, Yang N, Saucke MC, et al. Adoption of active surveillance for very low-risk differentiated thyroid cancer in the United States: a national survey. J Clin Endocrinol Metab. 2020;106(4):1728–37.CrossRefPubMedCentral
39.
Zurück zum Zitat Pasqual E, Sosa JA, Chen Y, Schonfeld SJ, de Gonzalez AB, Kitahara CM. Trends in the management of localized papillary thyroid carcinoma in the United States (2000–2018). Thyroid. 2022;32(4):397–410.CrossRefPubMedPubMedCentral Pasqual E, Sosa JA, Chen Y, Schonfeld SJ, de Gonzalez AB, Kitahara CM. Trends in the management of localized papillary thyroid carcinoma in the United States (2000–2018). Thyroid. 2022;32(4):397–410.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):1529–36.CrossRefPubMedPubMedCentral Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):1529–36.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ullmann TM, Papaleontiou M, Sosa JA. Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis. J Clin Endocrinol Metab. 2023;108(2):271–80.CrossRefPubMed Ullmann TM, Papaleontiou M, Sosa JA. Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis. J Clin Endocrinol Metab. 2023;108(2):271–80.CrossRefPubMed
Metadaten
Titel
Racial–Ethnic Comparison of Treatment for Papillary Thyroid Cancer in the Military Health System
verfasst von
Yvonne L. Eaglehouse, PhD, MPH
Sarah Darmon, PhD
Craig D. Shriver, MD
Kangmin Zhu, MD, PhD
Publikationsdatum
31.07.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15941-2

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.